However, Schmuck et al. only included ten patients for tumor volume monitoring under Lu-PSMA therapy and Grubmüller et al. employed an unusual interim PET timepoint after the third administration of Lu-PSMA therapy 14, 15. Here, FOLH1 is linked to neoplasm.